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Introduction
A non-coding RNA (ncRNA) is a functional RNA molecule 
that is not translated into a protein. Members of this class of 
molecule  are  involved  in  many  cellular  processes  and 
include highly abundant and functionally important RNAs, 
such as transfer RNA (tRNA) and ribo  somal RNA (rRNA), 
as  well  as  small  interfering  RNAs  (siRNAs),  microRNAs 
(miRNAs),  PIWI-associated  RNAs  (piRNAs),  small 
nucleolar  RNAs  (snoRNAs),  promoter-associated  RNAs 
(PARs) and the recently identified telomere specific small 
RNAs (tel-sRNAs). Moreover, the recent demonstration 
that other ncRNAs, the ultraconserved genes or trans-
cribed ultraconserved regions (T-UCRs) [1], are involved 
in human carcinogenesis suggests that the broad family 
of ncRNAs contributes to molecular alterations in several 
pathological conditions.
miRNAs  are  a  conserved  class  of  non-coding  RNAs 
that  regulate  the  translation  of  mRNAs  (messenger 
RNAs) by inhibiting ribosome function, decapping the 5’ 
cap structure, deadenylating the poly(A) tail and degrad-
ing target mRNAs [2]. miRNAs are involved in mecha-
nisms  of  gene  regulation  in  both  normal  and  diseased 
conditions and have a role during development, regula-
tion of cell proliferation and apoptosis. The first miRNAs 
were identified in the nematode Caenorhabditis elegans 
as small RNAs that interacted with the 3’ untranslated 
region (UTR) of the lin-14 mRNA to inhibit its expression 
[3]. miRNAs are single-stranded RNAs 19 to 24 nucleo-
tides in length generated through a complex maturation 
process [4,5] (Figure 1). miRNAs bind mostly to mRNA 
segments originating from the 3’ UTRs of genes [6], but 
the  mechanism  of  translational  repression  is  only 
partially understood.
siRNAs  are  small  RNAs,  21  to  22  nucleotides  long, 
produced  by  Dicer  cleavage  of  complementary  dsRNA 
duplexes.  siRNAs  form  complexes  with  Argonaute 
proteins and are involved in gene regulation, transposon 
control and defense against viruses.
piRNAs, 24 to 30 nucleotides in length, are produced 
by a Dicer-independent mechanism, associate with Piwi-
class Argonaute proteins and are principally restricted to 
the  germline  and  bordering  somatic  cells.  piRNAs  are 
important  for  transposon  control  [7,8]  and  regulate 
chroma  tin  state  [9].  A  recent  study  suggests  that  an 
antisense RNA may trigger transcriptional silencing of a 
partner sense tumor suppressor gene; this effect occurs 
both in cis and in trans and is Dicer-independent. The 
biochemical mediators of this silencing involve a Piwi-
like protein, and their role in mammals is just beginning 
to be understood [5,10]. In zebrafish, piRNAs have been 
implicated in germ cell maintenance and many of them 
were mapped to transposons, suggesting that they have a 
role in silencing repetitive elements in vertebrates [11]. 
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snoRNAs are small RNA molecules, approximately 60 
to 300 nucleotides long, which generally serve as guides 
for  the  catalytic  modification  of  selected  ribosomal 
RNAs [12,13]. In vertebrates, most snoRNAs have been 
shown to reside in introns of protein-coding host genes 
and  are  processed  out  of  the  excised  introns.  Many 
snoRNAs have been described as retrogenes [14]. Some 
snoRNA is processed to a small RNA that can function 
like a miRNA [15].
PARs  encompass  a  suite  of  long  and  short  RNAs, 
including promoter-associated small RNAs (PASRs) and 
transcriptional  initiation  RNAs,  that  overlap  promoter 
regions. Their function is so far unknown but they may 
possibly regulate transcription, as exogenous PASRs have 
been  observed  to  reduce  expression  of  genes  with 
homologous promoter sequences [16].
tel-sRNAs  in  mouse  embryonic  stem  cells  are 
approximately  24  nucleotides  long,  Dicer-independent, 
and 2’-O-methylated at the 3’ terminus. They are asym-
metric, with specificity for G-rich telomere strands, are 
evolutionarily  conserved  from  protozoa  to  mammals, 
and they may have a role in telomere maintenance [17].
Ultraconserved  region  (UCR)  sequences  are  longer 
than 200 nucleotides in the genomes of human, mouse 
and rat. These are DNA sequences absolutely conserved, 
showing 100% homology among species with no inser-
tions nor deletions [18]. UCRs can be located at fragile 
sites  and  genomic  regions  affected  in  various  cancers 
called cancer-associated genomic regions. Genome-wide 
profiling  has  revealed  that  UCRs  are  differentially 
expressed in cancer and leukemia [1,19].
Here,  we  discuss  the  basic  mechanisms  of  action  of 
human ncRNAs and review their clinical impact, includ-
ing their emerging roles in the pathogenesis of cancer, 
leukemia and other diseases. We then focus on recent 
progress and future directions in drug development using 
the  ‘ncRNA  strategy’.  The  identification  of  ncRNAs,  in 
particular miRNAs and their respective targets, provides 
a  host  of  potential  biomarkers  and  novel  therapeutic 
molecular tools.
snoRNAs and disease
Several  studies  have  shown  an  association  between 
snoRNAs and various diseases, including cancer. Prader-
Willi  syndrome  (PWS)  is  a  congenital  disease  that  is 
caused  by  the  loss  of  paternal  gene  expression  from  a 
maternally  imprinted  region  on  chromosome  15.  The 
SNORD115  snoRNA  (also  called  HBII-52)  shows 
sequence complementarities to the alternatively spliced 
exon Vb of the serotonin receptor 5-HT2C, located on 
chromosome X. HBII-52 regulates alternative splicing of 
5-HT2C by binding to a silencing element in exon Vb. 
PWS patients do not express HBII-52, so in this case the 
snoRNA seems to regulate the processing of an mRNA 
Figure 1. Schematic overview of miRNA processing and 
functions in cancer. Transcription from miRNA genes is under the 
regulation of transcription factors (TF) that respond to multiple 
signals and can also be epigenetically controlled. miRNA genes are 
transcribed by RNA polymerase II to produce a long nucleotide 
sequence, the pri-miRNA, which is cleaved by Drosha, a RNAse 
III endonuclease that recognizes internal hairpin structures. 
The resulting miRNA precursors (pre-miRNAs) of approximately 
70 nucleotides are actively exported by Exportin-5 into the 
cytoplasm. Once in the cytoplasm, the pre-miRNAs are further 
digested by Dicer (another RNAse III endonuclease), which yields 
21 to 22 nucleotide dsRNAs with two nucleotide overhangs (the 
miRNA* species is a rare non-miRNA cleavage product). Single 
strands from these dsRNAs associate with several members of the 
Argonaute (AGO) protein family to form the RNA induced silencing 
complex (RISC). The mRNA segments that miRNAs bind seem to be 
mostly in the 3’ UTRs. Overexpression (up arrow) of a miRNA could 
result in downregulation of a tumor suppressor, or underexpression 
(down arrow) of a miRNA could lead to upregulation of an oncogene. 
These events thus promote cell proliferation, decrease apoptosis and 
stimulate angiogenesis, leading to tumorigenesis.
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another  study  related  to  PWS  [21]  demonstrated  that 
deletion  of  Snord116  (also  called  Pwcr1  or  MBII-85) 
causes  growth  deficiency  and  hyperphagia  in  mice, 
revealing  a  novel  role  for  an  ncRNA  in  growth  and 
feeding regulation. snoRNAs have also been implicated 
in cancer development. The U50 snoRNA acts as a tumor 
suppressor  in  human  prostate  cancer  [22]  and  in  the 
development and/or progression of breast cancer [23].
Ultraconserved regions
There  are  481  UCRs  longer  than  200  bases  in  the 
genomes of human, mouse and rat [18]. Many of these 
elements  have  been  shown  to  have  tissue-specific 
enhancer  activity  [24,25],  and  another  subset  of  ultra-
conserved  elements  has  been  shown  to  be  associated 
with control of splicing regulators by alternative splicing 
and  nonsense-mediated  decay  [26].  The  functional 
impor  tance of UCRs has been emphasized by genome-
wide profiling, which revealed distinct UCR signatures in 
human leukemias and carcinomas. Calin et al. [1] have 
shown  that  some  UCRs,  whose  expression  may  be 
regulated by miRNAs, are abnormally expressed in human 
chronic  lymphocytic  leukemia  (CLL),  and  that  the 
inhibition of an overexpressed UCR induces apop  tosis in 
colon cancer cells. The correlation between the expression 
of UCRs and miRNAs in CLL patients raised the possibility 
of  functional  pathways  in  which  two  or  more  types  of 
ncRNAs interact. This implication may support a model in 
which both coding and non-coding genes are involved and 
cooperate in human tumorigenesis.
miRNAs and disease
miRNAs in leukemia
The  role  of  miRNA  in  cancer  was  first  discovered  in 
leukemia. Calin et al. [27] reported evidence for the role 
of miRNAs in the pathogenesis of CLL: deletions and/or 
downregulation of miR-15a and miR-16-1 at 13q14 were 
associated with CLL. Cimmino et al. [28] demonstrated 
that this cluster can regulate the expression of the B-cell 
lymphoma 2 (BCL-2) oncogene. Other relevant altera  tions 
of miRNAs in CLL include downregulation of miR-181a, 
let-7a,  miR-30d,  miR-150  and  miR-92  [29]  and  over-
expression  of  miR-155.  In  Table  1  are  shown  the  most 
important miRNAs associated with leukemia and hemato-
logical diseases. For example, miRNAs in the miR17-92 
cluster  are  commonly  amplified  in  B-cell  lymphoma 
patients and, together with miR-155, they were among 
the earliest ncRNAs to be linked with cancer [28].
miRNA expression signatures have revealed differences 
between acute lymphoblastic leukemia (ALL) and acute 
myeloid leukemia (AML) [30]. Recently, specific miRNA 
signatures were correlated with karyotype alterations in 
AML:  the  main  observation  was  that  the  t(15;17) 
translocation  had  a  distinctive  signature  including  the 
upregulation of a subset of miRNAs located in the human 
14q32 imprinted domain. In another study, Garzon and 
colleagues  [31]  reported  miRNA  signatures  associated 
with cytogenetics and prognosis of AML, with molecular 
abnormalities  such  as  t(11q23),  trisomy  8  and  internal 
tandem duplications in the FLT3 receptor tyrosine kinase 
gene.  Downregulation  of  miR-221  and  miR-222  was 
observed in AML [32]. Bueno et al. [33] revealed a new 
dimension  to  the  regulation  of  v-Abl  Abelson  murine 
leukemia viral oncogene homolog 1 (ABL1) expression by 
demonstrating that ABL1 is a direct target of miR-203. 
miR-203  is  silenced  by  genetic  and  epigenetic  mecha-
nisms  in  hematopoietic  malignancies  expressing  either 
ABL1 or BCR-ABL1. Restoration of miR-203 expression 
reduces  ABL1  and  BCR-ABL1  levels  and  inhibits  cell 
proliferation. Venturini and co-workers [34] have shown 
the  expression  of  the  miR-17-92  polycistron  in  CD34+ 
cells in chronic myelogenous leukemia and the regulation 
of this cluster by BCR-ABL1 and c-MYC.
miRNAs in solid cancers
Immediately after the first reports on the involvement of 
miRNAs in leukemia and lymphoma, a flurry of reports 
unveiled a role for miRNAs in solid cancers. The availa-
bility of high-throughput techniques for miRNA profiling 
allowed  a  detailed  investigation  of  many  cancer  types. 
These  studies  immediately  showed  that  miRNAs  are 
Table 1. Relevant miRNAs associated with leukemia
Blood malignancy miRNA Regulation References
CLL miR-15a miR-16-1, miR-181a, let-7a, miR-30d, miR-150, miR-92 Downregulation [28,29]
Pediatric Burkitt’s lymphoma, Hodgkin’s lymphoma, 
diffuse large B cell lymphoma
miR-155, miR-17-92 Upregulation [28,29,72]
Hodgkin’s disease, Burkitt lymphoma cells miR-9, let-7a Upregulation [73,74]
B cell malignancies miR-143, miR-145 Downregulation [75]
AML miR-127, miR-154, miR-299, miR-323, miR-368, miR-370  Upregulation [30,76]
AML miR-221, miR-222 Downregulation [31,32]
Hematopoietic malignancies miR-203 Downregulation [33]
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can be used to classify tumors of different origins [35,36]. 
Table 2 shows a summary of known miRNAs correlated 
with solid cancers.
Some miRNAs that had been earlier characterized in 
leukemia were found to be commonly overexpressed in 
solid  cancers:  miR-17-5p,  miR-20a,  miR-21,  miR-92, 
miR-106a,  miR-107,  miR-146,  miR-155,  miR-181  and 
miR-221/222 [36]. Other miRNAs were characterized in 
relation to specific tumor types. For example, miR-21 was 
highly expressed in breast tumors [37] and a risk variant 
of a miR-125b binding site in the bone morphogenetic 
protein  receptor  type  IB  gene  (BMPR1B)  was  also 
associated with breast cancer pathogenesis [38,39]. The 
overexpressed miR-106b/93/25 cluster modulated an anti-
apoptotic response after TGF-β stimulation mediated by 
BCL2-like 11 (BIM) [40]. Various studies on pancreatic 
cancer highlighted significant differences between tumors 
and chronic pancreatitis, normal pancreas and pancreatic 
cell lines. Pancreatic tumors have a characteristic miRNA 
profile; a pancreatic ductal adenocarcinoma-related miRNA 
signature  was  defined  [41].  In  a  study  on  65  resected 
pancreatic ductal adenocarcinomas with matched benign 
adjacent pancreas by Bloomston et al. [42], miR-196a was 
associated with poor survival. Several studies have shown 
that  specific  miRNAs  are  aberrantly  expressed  in 
malignant  hepatocellular  carcinoma  compared  with 
normal  hepatocytes  [43,44].  The  altered  expression  of 
some miRNAs has been associated with particular risk 
factors, such as hepatitis B virus infection or alcohol use 
[44].  Many  of  these  miRNAs  are  upregulated  in 
hepatocellular  carcinoma  as  compared  with  normal 
thyroid cells and hyperplastic nodules [45].
miRNAs as oncogenes and tumor suppressors
By  targeting  and  controlling  the  expression  of  mRNA, 
miRNAs can control highly complex signal-transduction 
pathways and other biological pathways. The biological 
roles  of  miRNAs  in  cancer  suggest  a  correlation  with 
prognosis  and  therapeutic  outcome.  A  study  [46] 
demonstrated that more than 50% of miRNA genes are 
located in cancer-associated genomic regions or in fragile 
sites, suggesting that miRNAs may be more important in 
the  pathogenesis  of  human  cancers  than  previously 
thought. miRNAs are also involved in advanced stages of 
tumor  progression,  which  underlines  their  roles  as 
metastasis activators or suppressors.
There  is  emerging  evidence  that  some  miRNAs  can 
function  as  either  oncogenes  or  tumor  suppressors. 
Those miRNAs whose expression is increased in tumors 
may be considered as oncogenes - also called ‘oncomiRs’ - 
which promote tumor development by inhibiting tumor 
suppressor genes and/or genes controlling cell differen-
tiation or apoptosis.
The miR-17-92 cluster is an miRNA polycistron located 
at chromosome 13q31, a genomic locus that is amplified in 
lung cancer and in several kinds of lymphoma, includ  ing 
diffuse large B-cell lymphoma. This cluster has been found 
to  be  regulated  by  c-MYC,  an  important  trans  crip  tion 
factor that is overexpressed in many human cancers [47].
Microarray analysis revealed that miR-221, miR-21 and 
miR-181a/b/c  are  strongly  upregulated  in  glioblastoma 
samples compared with normal brain controls [48]. The 
data  suggested  that  these  miRNAs  may  act  as  anti-
apoptotic factors in human malignant disease. In several 
types of lymphomas, including Burkitt’s lymphoma, the 
expression  of  miR-155  is  increased  [49].  Furthermore, 
miR-155 is located in the only phylogenetically conserved 
region  of  the  B-cell  receptor  inducible  (BIC)  gene, 
suggesting  that  miR-155  may  be  responsible  for  BIC’s 
oncogenic activity [50].
Conversely, underexpressed miRNAs in cancers, such 
as  some  members  of  the  let-7  family,  may  function  as 
tumor suppressor genes by regulating oncogenes and/or 
Table 2. Overview of prominent miRNAs associated with solid cancers
Type of solid cancer miRNA Function References
Breast cancer miR-21, miR-125b oncomiR [37]
Breast cancer metastasis miR-335, miR-206, miR-126 Metastasis suppressor [77,78]
Lung adenocarcinoma let-7a, miR-143, miR-145 Tumor suppressor [32,39]
Lung adenocarcinoma miR-17-92 cluster, miR-106b/93/25 cluster oncomiR [32,40]
Pancreatic ductal carcinoma miR-196a, miR-196b oncomiR [41,42]
Ovarian carcinoma miR-199a/b, miR-140, miR-145, miR-204, miR-125a/b Tumor suppressor [79]
Ovarian carcinoma miR-141, miR-200a/b/c  oncomiR [79]
Hepatocellular carcinoma  miR-21, miR-224, miR-34a, miR-221/222, miR-106a, miR-203 oncomiR [43,44]
Hepatocellular carcinoma miR-122a, miR-422b, miR-145, miR-199a Tumor suppressor [43,44]
Thyroid papillary cancer miR-146b, miR-221, miR-222, miR-181b, miR-155, miR-224 oncomiR [45,78,80]
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Several studies indicate that the RAS oncogene is a direct 
target of let-7, which negatively regulates RAS by pairing 
to  its  3’  UTR  for  translational  repression,  and  some 
recent studies have focused on let-7 miRNA binding site 
polymorphisms  in  the  KRAS  3’  UTR  that  have  been 
associated  with  reduced  survival  in  oral  cancers  [51]. 
Other  miRNAs  that  have  a  potential  role  as  tumor 
suppressors  include  miR-15 and  miR-16,  which induce 
apoptosis by targeting the mRNAs for the anti-apoptotic 
gene  B-cell  lymphoma  2  (BCL-2)  [28],  myeloid  cell 
leukemia sequence 1 (MCL1), cyclin D1 (CCND1) and 
wingless-type MMTV integration site family member 3A 
(WNT3A)  [52].  Downregulation  of  these  miRNAs  has 
been reported in CLL, pituitary adenomas and prostate 
carcinoma. Restoration of miR-29b in AML cells induces 
apoptosis and dramatically reduces tumorigenicity in a 
xenograft leukemia model: this study also indicated that 
miR-29b  targets  apoptosis,  cell  cycle  and  proliferation 
pathways [31].
miR-221 and miR-222 are two highly similar miRNAs 
whose  upregulation  has  been  recently  described  in 
several types of human tumors and for which an onco-
genic role was explained by the discovery of their target 
p27, a key cell cycle regulator. The ectopic overexpression 
of miR-221 is able, on its own, to confer a high growth 
advantage to tumors derived from the LNCaP cell line in 
severe combined immunodeficient mice [53]. In line with 
these  results,  treatment  of  established  subcutaneous 
tumors derived from the highly aggressive PC3 cell line 
with  the  anti-miR-221/222  antagomiR  (an  anti-miRNA 
conjugated  to  cholesterol)  reduced  tumor  growth  by 
increasing  expression  of  the  cyclin-dependent  kinase 
inhibitor p27 [53]. These findings suggest that modulating 
levels of let-7, miR-15, miR-16, miR-221/222 or miR-29b 
might  be  of  therapeutic  potential  in  various  different 
types of cancers.
miRNAs in tumor invasion and metastasis
The first description of a miRNA in relation to tumor 
invasion  and  metastasis  was  by  Ma  et  al.  [54],  who 
identified  miR-10b  upregulation  in  metastatic  breast 
cancer cells with respect to the primary tumors. miR-10b 
was  expressed  in  breast  cancer  in  the  following  way: 
down  regulated  in  cancer  when  compared  with  normal 
breast [32] but overexpressed in metastatic cancer when 
compared  with  non-metastatic  tumors  [54].  Subse-
quently,  Huang  and  colleagues  [55]  identified  two 
miRNAs, miR-373 and miR-520c, that promote cancer 
cell migration and invasion in vitro and in vivo by block-
ing  the  adhesion  molecule  CD44.  A  significant  up-
regulation  of  miR-373  and  negative  correlation  with 
CD44  expression  was  found  in  breast  cancer  patients 
with metastasis.
Recently, much interest has been focused on the role of 
miRNAs in the maintenance of the so-called ‘cancer stem 
cells’. Human breast tumors contain a breast cancer stem 
cell  (BCSC)  population  with  properties  reminiscent  of 
normal stem cells. Three miRNA clusters, miR-200c/141, 
miR-200b/200a/429 and miR-183/96/182, are down  regu-
lated  in  human  BCSCs,  normal  human  and  murine 
mammary  stem/progenitor  cells  and  embryonic  carci-
noma  cells.  miR-200c  modulates  expression  of  B 
lymphoma Mo-MLV insertion region 1 homolog (BMI1), 
an  essential  protein  for  the  self-renewal  of  adult  stem 
cells. miR-200c suppresses normal mammary outgrowth 
in  vivo  and  tumorigenicity  of  human  BCSCs.  The 
coordinated  downregulation  of  these  miRNA  clusters, 
and the analogous regulation of clonal expansion by miR-
200c, provides a molecular link that connects BCSCs to 
normal stem cells [56].
From in vitro findings to clinical biomarkers and 
therapies
Because of their links to pathological conditions and, in 
particular,  cancer  development  and  progression, 
miRNAs  and  other  ncRNAs  might  become  useful 
biomarkers for diagnostic purposes. ncRNA expression 
levels can be determined by in situ hybridization, for 
example  on  a  tumor  section  and  its  normal  adjacent 
counterparts.  Mature-miRNA-specific  stem  loop  RT-
PCR is an alternative detection system for very short 
ncRNAs. Recently, deep-sequencing technologies, such 
as  SOLiD  (Applied  Biosystems,  Foster  City,  USA)  or 
Genome  Analyzer  (Illumina,  San  Diego,  USA),  have 
become  avail  able  for  high-throughput  detection  of 
ncRNAs.
The  key  question  is  how  to  translate  the  molecular 
signatures  determined  in  the  laboratory  to  the  clinical 
setting. As described above, several studies have identi-
fied  associations  of  miRNA  with  disease  prognosis, 
survival and mortality in biopsies (in pancreatic cancer 
[42]  and  colon  cancer  [57]).  A  possible  innovative 
approach for early detection is represented by the deter-
mination of circulating miRNAs in plasma [58] or urine. 
In an application of this approach, Tanaka et al. [58] have 
shown that miR-92a levels are decreased in the plasma of 
leukemia patients and suggested the ratio in plasma of 
miR-92a  to  miR-638  (the  latter  is  stably  expressed  in 
human  plasma)  as  a  tool  for  the  clinical  detection  of 
leukemia. Differential expression of miRNAs in plasma of 
patients with colorectal cancer has also been proposed as 
a basis for screening [59].
Non-oncological  disciplines  could  also  benefit  from 
measuring circulating ncRNAs. For example, the plasma 
concentration of miR-208 might be a useful indicator of 
myocardial  injury  [60].  Plasma  miRNAs  and  other 
circulating  or  secreted  ncRNAs  therefore  represent 
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pathological conditions.
Therapeutic silencing and inhibition of ncRNAs
The  fundamental  roles  of  miRNAs  in  development, 
differentiation and malignancy suggest that this class of 
molecules  are  potential  targets  for  novel  therapeutics. 
Antisense  oligonucleotide  approaches,  used  for  inhibi-
tion, and siRNA-like technologies, used for replacement, 
are currently being explored for therapeutic modulation 
of miRNAs.
There  are  currently  several  approaches  to  silencing 
ncRNAs  (Table  3).  Most  of  these  methods  have  been 
applied to miRNAs, the class of ncRNAs that currently 
holds  the  highest  potential  for  clinical  applications. 
Specific  knockdown  of  miRNAs  by  anti-miRNA  oligo-
nucleotides  (AMOs),  double-strand  miRNA  mimetics 
and  overexpression  of  miRNA  duplexes  have  been 
conducted in vitro and in vivo (Table 4). AntagomiRs have 
been  found  capable  of  inhibiting  specific  miRNAs  in 
mouse  models.  RNase  H-based  AMOs,  which  work 
primarily  in  the  nucleus,  may  be  useful  for  targeting 
polycistronic pri-miRNAs, such as the miR-17-92 cluster 
[61].  Elmen  et  al.  [62]  showed  that  systemic 
administration  of  16-nucleotide  unconjugated  locked 
nucleic acid (LNA)-AMO complementary to the 5’ end of 
miR-122  leads  to  specific,  dose-dependent  silencing  of 
miR-122 with no hepatotoxicity in mice. Another study 
from  the  same  group  demonstrated  that  the  simple 
systemic  delivery  of  an  unconjugated  LNA-AMO 
effectively  antagonizes  the  liver-expressed  miR-122  in 
non-human  primates.  Acute  administration  by 
intravenous injections of 3 or 10 mg/kg LNA-AMO to 
African  green  monkeys  resulted  in  uptake  of  the 
LNA-AMO in the cytoplasm of primate hepatocytes and 
formation  of  stable  heteroduplexes  between  the 
LNA-AMO and miR-122 [63]. This route seems attractive 
for  in  vivo  applications  that  are  inaccessible  to  RNA 
inter  ference technology, such as inhibition of oncogenic 
miRNAs.
Strategies based on synthetic miRNAs may also open 
interesting  avenues.  Recently,  Tsuda  et  al.  [64,65] 
Table 3. Methodological characteristics of chemical and biological therapeutic tools*
Therapeutic 
modulation Chemical-biological characteristics Strategies Delivery system Clinical application References
2’-Ome AMOs Modified 2-OH residues of the ribose 
2’-O-methyl
Inhibition of mature 
miRNA
RNA-liposome complex; 
conjugation of a cholesterol
Silence oncomiR [81-83]
2’-MOE AMOs Modified 2-OH residues of the ribose 
2’-O-methoxyethyl
Inhibition of mature 
miRNA
Oligonucleotide-liposome 
complex; conjugation of a 
cholesterol
Silence oncomiR [81-83]
AMOs (RNase 
H-based)
Contains a short stretch of centrally 
located 2’ deoxy residues
Inhibition of pri-miRNA Oligonucleotide-liposome 
complex; conjugation of a 
cholesterol
Silence polycistronic 
miRNA cluster
[61,84]
LNA-antagomiR Contains one or more nucleotide 
building blocks in which an extra 
methylene bridge fixes the ribose 
moiety either in C3’-endo or C2’-endo 
conformation1
Inhibition of mature 
miRNA
Unconjugated Silence oncomiR [63]
pre-miRNA-like 
shRNAs
Natural pre-miRNA, for a more persistent 
miRNA replacement
Replacement of mature 
miRNA
Plasmid or viral vector with 
either polymerase II or III 
promoter upstream of a 
shRNA
Restore tumor 
suppressor miRNA
[85,86]
Double-stranded 
miRNA mimetics
Equivalent to endogenous Dicer 
product; analogous structure to an siRNA
Replacement of mature 
miRNA
Oligonucleotide-liposome 
complex; conjugation of 
a cholesterol; linking with 
delivery proteins; other 
nanotechnology-based 
conjugation; transgene 
approach
Restore tumor 
suppressor miRNA
[87]
Synthetic 
miRNAs
Designed related target mRNA Selected silence target Conjugation of a protein 
interaction target
Tumor suppressor role [64,65]
‘miRNA sponges’ Multiple miRNA binding sites into the 
3’ UTR of a reporter gene encoding 
destabilized GFP driven by the CMV 
promoter
Inhibition of mature 
miRNA cluster
Sponge plasmid vector Silence oncomiR family [66]
*Abbreviations: GFP, green fluorescent protein; CMV, cytomegalovirus.
1C3’-endo (beta-D-LNA) or C2’-endo (alpha-L-LNA) stereoisomer.
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ing to duplex miRNAs by introducing 3-nucleotide loops 
in GU-rich regions of the 3’ UTR sequence of the glioma-
associated antigen-1 (Gli-1) gene. They found that one of 
these (Gli-1-miRNA-3548) and its corresponding duplex 
(Duplex-3548)  inhibited  proliferation  of  Gli-1+  ovarian 
and pancreatic tumor cells.
An  alternative  to  chemically  modified  anti-ncRNA 
oligonucleotides  is  offered  by  de  novo  engineered 
ncRNA inhibitors that can be exogenously expressed in 
cells. These ‘miRNA sponges’ are competitive inhibitors 
to  trans  cripts  expressed  from  strong  promoters, 
containing multiple, tandem binding sites of an miRNA 
of  interest.  Sponges  inhibit  miRNAs  with  a 
complementary  heptameric  seed,  such  that  a  single 
sponge can be used to block an entire miRNA family 
with the same seed. Fluorescent reporter genes can be 
used to identify and sort the treated cells [66]. Another 
route to therapeutic targeting of ncRNAs, in particular 
miRNAs, could be represented by inhibition of Drosha, 
Dicer or other components in the maturation pathway. 
This  method,  stepping  into  a  pleiotropic  physiological 
pathway, may, however, be difficult to make specific in 
its therapeutic effect.
Therapeutic replacement or re-activation of ncRNAs
When  ncRNA  activity  is  lost  in  affected  cells,  an 
alternative  therapeutic  strategy  is  needed.  Here  the 
approach is represented by the ‘replacement’ of defective 
or absent RNA effectors. An example of such an approach 
is  the  use,  as  described  earlier  for  the  miR-29b  tumor 
suppressor, of synthetic oligonucleotides, in this particu-
lar case aimed at improving treatment response in AML 
[31].  Gene  therapy  approaches  for  therapeutic  miRNA 
replacement  hold  considerable  potential.  Modified 
adeno  virus or adeno-associated virus vectors have been 
effective  for  gene  delivery  into  tissues.  Nevertheless,  a 
study  [67]  has  also  shown  that  such  an  approach  can 
cause  fatality  in  mice,  possibly  resulting  from  over-
saturation  of  the  cellular  miRNA/short  hairpin  RNA 
pathway (shRNA; a short sequence of RNA that makes a 
tight  hairpin  turn  and  can  be  used  to  silence  gene 
expression). Lentiviral delivery of short hairpin RNAs is 
another  system  for  the  delivery  of  shRNA  constructs 
(controlled by either RNA polymerase II or III promoters) 
designed  to  mimic  the  pri-miRNA  by  including  the 
miRNA flanking sequence into the shRNA stem [68,69]. 
The  multi-inlet  focusing  technique  used  for  the  Bcl-2 
antisense deoxyoligonucleotide [70] can be extended to 
Table 4. Overview of in vivo delivery systems for snoRNAs and miRNAs*
miRNA Disease state Biological target In vivo model Delivery system References
miR-100 Nasopharyngeal cancer Plk1 6- to 8-week-old SCID BALB/c 
female mice
siRNA and ionizing radiation and 
potential miRNAs that might 
regulate Plk1 expression
[88]
Synthetic miR-16 Metastatic prostate cancer CDK1 and CDK2 Bone metastasis mode mice Injected into tail veins [89]
miR-155 Myeloproliferative disorder SHIP1 Mice, specific knockdown of 
SHIP1 in the hematopoietic 
system
Retroviral delivery of a miR-155-
formatted siRNA against SHIP1
[90]
SNORD116 
(PWCR1/HBII-85)
Prader-Willi syndrome Bioinformatic screen 
located 23 possible 
targets
C57BL/6 mice Snord116del mice [21]
miR-147 Inflammation Cytokine expression in 
macrophages stimulated 
with ligands to Toll-like 
receptors: TLR2, TLR3, 
TLR4
LPS-stimulated mouse Peritoneal macrophages were 
transfected with 40 nM control 
miRNA mimics or mouse miR-147 
mimics
[91]
LNA-antimiR-122 Hypercholesterolemia miR-122 liver specific Normal and 
hypercholesterolemic 
mice; normal African green 
monkeys
Intravenous injections 
unconjugated
[62]
LNA-antimiR-21 Glioma miR-21 Athymic nude mice Intracranial cell implantation [92]
miR-34a Normal E2F family Nude mice Subcutaneous administration of 
miR-34a/collagen complexes
[93]
mir-17-92 cluster Normal c-Myc Mice reconstituted with 
hematopoietic stem cells 
expressing mir-17-19b
Perfusion cells treated by 
retroviral vector
[94]
*Abbreviations: CDK, cyclin-dependent kinase; E2F, E2 transcription factor; LPS, lipopolysaccharide; Plk1, Polo-like kinase 1; SCID, severe combined immunodeficient; 
SHIP1, Src homology-2 domain-containing inositol 5-phosphatase 1; TLR, Toll-like receptor.
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transfection  efficiency  faced  by  delivery  of  ‘naked’ 
miRNAs. Moreover, epigenetic modifications of miRNAs, 
such as methylation, suggest the use of epigenetic therapy 
with drugs that modulate DNA methylation or histone 
deacetylation. Activation of tumor suppressor miRNAs, 
such  as  miR-127,  by  chromatin-modifying  drugs  may 
inhibit  tumor  growth  through  downregulation  of  their 
target oncogenes [71].
Conclusions and perspectives
ncRNAs  represent  a  novel  kind  of  human  post-
transcriptional  regulatory  tool.  They  can  specifically 
target different genes, often in a one-to-many manner. 
Fine-tuning the level of a single ncRNA might therefore 
affect  many  pathways  in  a  pleiotropic  manner.  Several 
studies  have  contributed  to  our  understanding  of  the 
functions of ncRNAs and of their impact on the patho-
genesis of complex diseases. Abnormal miRNA expres-
sion  is  now  regarded  as  an  intrinsic  feature  of  cancer 
growth and progression. These observations highlight the 
clinical potential of ncRNAs as biomarkers for diagnosis, 
prognosis  and  prediction  of  therapeutic  outcome. 
Because of the significant impact of miRNAs, it would be 
useful to develop a personalized expression dataset such 
as  a  ‘molecular  diagnostic  database’.  The  new  deep 
sequencing technologies might here provide the ability to 
translate  laboratory  potential  into  clinical  practice. 
Inhibition and re-activation of ncRNAs will then be the 
final steps in this discovery chain, leading to a therapeutic 
approach.  Engineered  synthetic  miRNAs  could  be 
custom-applied  to  specifically  regulate  gene  expression 
based on the patient’s genomic profile.
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